Update, November 5, 2026
HCA Healthcare (HCA) has added 7.6% over the last five sessions, closing at $514.50 on November 5, 2026, as the stock continues to lead both the S&P 500 (down 2.8% over the same period) and the XLV health care ETF (up 3.7%). The move has been driven by a broad post-midterm rally in hospital operators, with the Democratic sweep raising hopes for expanded Medicaid funding — a theme highlighted by Forbes and Morningstar. HCA's 50-day relative strength versus the S&P 500 stands at +19.3%, and versus XLV at +5.7%.
The picture holds. The stock remains above its 40-week average, and the daily trend is aligned with the weekly uptrend. The breakout level from the November 3 report — a daily close above 523.02 on volume above the 20-day average — is still intact, though the stock is now just 1.7% below that level. The stop at 495.5 (round 500 minus a quarter of ATR) and the first support at 500.0 are unchanged. The 52-week high target of 545.13 remains the next objective, but the reward-to-risk from the breakout level is still only 0.8, so the math has not improved. What would change the picture is a weekly close below 478.88, which would break the swing zone and end the uptrend.
Volume on the breakout day was 64% below the 20-day average, so the move lacks confirmation. The stock is now 8.2% above the average analyst target of $475.45, per 22 analysts, though BofA recently raised its target to $500. The next earnings date is January 26, 2027.
HCA Healthcare shares trade at $465.48 on November 3, 2026, 2.6% below the October 29 closing peak of $478.08, after a third-quarter report that beat estimates and lifted the company's 2026 outlook. The weekly uptrend is intact and HCA is leading the S&P 500, so the balance of evidence for the next two to six weeks leans positive, with medium conviction. The breakout math from $475 is thin, though, at under 1 to 1.
Why it matters
The event was the third-quarter report. Revenue came in at $19.85 billion, about 4% higher than a year earlier, against a consensus of $19.33 billion, and adjusted earnings were $7.22 a share against an estimate of $6.66, Benzinga reported. Net income was $1.58 billion, down 4%, while diluted earnings per share rose 4% to $7.27, according to the 10-Q filed on October 29. A clear beat and a higher full-year outlook are what the stock needed after the July guidance cut.
The reaction was not instant. On the day of the report, shares fell because the cost of treating uninsured patients offset revenue growth, Morningstar said. The stock then recovered and closed at $478.08 on October 29, and it is up 9.1% over the past month. Since that peak it has slipped 2.6%, including 0.5% today, on volume running well below its 20-day average (the session is not over). No news explains that pullback. The November 2 filing for a senior notes offering, which may fund redemption of $1.2 billion of 4.500% notes, is a financing step, not a signal about operations.
Most of the last five days' gain came from the sector. HCA rose 3.4% while the S&P 500 fell 2.1% and the health care sector fund XLV gained 2.8%. That leaves about 0.6 points that belong to the stock itself. HCA is moving with health care, not against the market for its own reasons. Over 50 days it leads the S&P 500 by 7.9 points but trails XLV by 0.7.
The real argument is about the quality of earnings and the policy backdrop. On the constructive side, BofA raised its price target to $500 from $450 and kept a Neutral rating, Investing.com reported, citing supplemental Medicaid programs and solid execution at a higher multiple of 10.5 times 2027 EBITDA. A Seeking Alpha piece takes a neutral line: payer mix pressures are real, broad trends are on track, and the shares trade at about 15 times forward earnings.
The cautious side has two strands. The Wall Street Journal says investors are betting on hospital operators in the hope that a Democratic House reverses Medicaid cuts, and warns that such rollbacks are hard to deliver. Separately, a law firm announced an investigation tied to the July 14 guidance cut, which it attributes to an unfavorable payer mix shift, in a PR Newswire release. That is an investigation, not a finding, but it keeps payer mix in focus.
On valuation, 22 analysts rate the stock a buy, with a mean price target of $475.45 and a spread from $380 to $550. At $465.48 the shares sit 2.1% below that mean. The consensus sees modest upside, not a large gap, and the wide spread shows how much the payer mix and Medicaid questions still divide opinion.
What the evidence says
For the long term, the thesis is intact but not fully repaired. The price is above its 40-week average, and above both the 200-day average at $444.29 and the 50-day at $438.91. The stock is up 7.5% over six months but roughly flat for the year (down 0.3%), and it is 14.6% below its 52-week high of $545.13. That pattern is a recovery inside a larger drawdown: the trend has turned up, and the prior high is still far away.
For the next two to six weeks, the balance of evidence leans positive, at medium conviction: two of four points. The daily trend runs with the weekly uptrend, and the 50-day relative strength against the S&P 500 is strongly in the stock's favor. Against that, HCA lags XLV over 50 days, which runs against the trend, and momentum is neutral, with the 14-day RSI at 47.6.
The strongest case against this reading is the setup of the move itself. The stock has pulled back from its peak on light volume, it lags its own sector over 50 days, and the Medicaid hopes in the WSJ piece may be priced in before any policy exists. Those points are why conviction is medium, not high. They do not tip the balance because the trend structure is still intact and the pullback has not broken any support.
Levels that matter
The structure holds above $461.11, a swing zone just under the current price. A move below it would be the first crack, though not a trend change. Below that, $450 is a round-number level, and the trend ends under $444.29, the 200-day average, which also sits near the 50-day at $438.91. Those levels matter because they are where earlier buyers and sellers acted and where the longer averages sit.
The breakout level is a daily close above $475 on volume above its 20-day average. Today's volume is far below that mark. From $475, the first target is $478.88 and the second $487.90, both swing zones. Against a stop at $457.20 (the $461.11 swing zone minus a quarter of the 14-day ATR of $15.64), the reward-to-risk is 0.2 to 1 at the first target and 0.7 to 1 at the second. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a much larger reward or a much closer stop, and nothing on the current map up to $521.51 gets there.
What would change the picture
The rule is a weekly close below $444.29, the 200-day average. That would put the stock under the long-term line that currently supports the recovery. The non-price fact that would most likely cause it is a new guidance cut tied to payer mix or uninsured costs, which would repeat the July pattern and undercut the claim that the third-quarter beat was durable.
What to watch
- Next earnings, January 26, 2027: adjusted earnings per share against the $7.22 delivered this quarter, and whether the full-year outlook holds without another payer mix warning.
- Sector and policy events: hospital policy after the midterm elections and Medicaid funding headlines, which can move HCA and XLV before any company news.
- Valuation against consensus: $465.48 against a $475.45 mean price target, with BofA at $500 and a full range of $380 to $550.